與傳統刺激膠原蛋白增生的產品不同，這項療程將處理過的細胞外基質直接注入臉部與頸部，為老化或受損的皮膚提供重建的支架。隨著全球抗老市場需求快速增長，該公司正積極擴大產能，並計畫將產品出口至美國及亞洲多個國家。
然而，這股熱潮也引發了倫理與安全方面的爭議。批評者擔憂將捐贈的人體組織用於醫美可能排擠原本燒燙傷或重建手術的醫療資源，並呼籲政府制定更嚴格的規範；儘管廠商強調其產品經過嚴格認證且捐贈同意書已涵蓋醫美用途，社會輿論對此仍存在分歧。
A new anti-aging treatment called Re2O, derived from donated human tissue, has recently emerged in South Korea's cosmetic medicine industry. Despite sounding like science fiction, this product, which fills fine lines and rebuilds skin structure, has become extremely popular, causing long clinic queues and a massive surge in stock price and profits for its biotech manufacturer, L&C Bio.
Unlike traditional products that stimulate collagen production, this treatment directly injects processed extracellular matrix into the face and neck, providing a reconstructive scaffold for aging or damaged skin. As global demand in the anti-aging market grows rapidly, the company is aggressively expanding its production capacity and plans to export the product to the United States and multiple countries in Asia.
However, this boom has also sparked ethical and safety controversies. Critics worry that using donated human tissue for cosmetic procedures might divert essential medical resources originally intended for burn treatments or reconstructive surgeries, prompting calls for stricter government regulations. Although the manufacturer emphasizes that its products are strictly certified and that donation consent forms cover cosmetic use, public opinion on the issue remains divided.